MKI67 and metastatic neoplasm: Lusby et al. (2013), reported Ki-67 overexpression, with an accompanying loss of ER and PR expression in case of LMS, whereas in metastatic tumors Ki-67 expression with VEGF and survival was higher as compared to the primary foci [74].